The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.本發明提供新穎呋喃酮化合物,或其醫藥學上可接受之鹽、溶劑合物或前藥,作為Raf激酶抑制劑,尤其BRAF激酶抑制劑,其為用於治療Raf激酶相關疾病或病症(諸如黑素瘤、癌症及白血病)之有效治療劑。本發明亦提供用於製備此等新穎呋喃酮化合物之方法及製程、含有此等呋喃酮化合物之醫藥組合物,及使用此等呋喃酮化合物之治療方法。
